ClinicalTrials.gg
RecruitingNCT07347405Mushroom-OCDUpdated Jul 23, 2026

Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder.

A Phase 1 interventional study of Psilocybin 10 mg and Psilocybin 20 mg in Obsessive-Compulsive Disorder, sponsored by Francisco A Moreno. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Francisco A Moreno · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 299 studies in Obsessive-Compulsive Disorder with a site in United States — 59 open to participants now, 77 under way, 2 of them phase 3. Obsessive-Compulsive Disorder · United States.

Planned enrollment
142nd of 246
30 · median 40
Started
2026
with 12 others
Phase 1
11 of 299
1 open now
Primary completion
2028-12
later than 54 of 76 live
Registered
292nd of 299
by date

Among the 299 studies in Obsessive-Compulsive Disorder with a site in United States, this one is the 142nd largest by planned enrollment of the 246 interventional ones that give a count, is one of 13 that started in 2026, is one of 11 in phase 1, reaches primary completion later than 54 of the 76 other live ones, and was the 292nd registered.

Obsessive-Compulsive Disorder

637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.

Browse Obsessive-Compulsive Disorder studies →

Open to participants now

59 of the 299 studies in Obsessive-Compulsive Disorder with a site in United States are open now. Recruiting first, the newest first:

53 more — sign in →

All 59 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 299 studies in Obsessive-Compulsive Disorder with a site in United States, or all of them as a file.
02

Study summary

The study tries to improve our treatments for people who have obsessive-compulsive disorder (OCD) by testing psilocybin, a mind altering drug that changes activity in brain areas involved in OCD. 30 patients with moderate or more severe OCD who are not taking mind altering medications or street drugs will participate in a 12 week study. Participants will be assigned (by luck of the draw) to take a low, medium, or high dose whole psilocybin mushroom contained in three chocolate pieces, prepared for this study by the Scottsdale Research Institute.

Read the detailed description

Participants will come to the University of Arizona CATS Research Unit in Tucson for assessment, if they are found to be fit for study participation, they will be scheduled for a preparation session with a study therapist and then will participate in a dosing session when they will ingest three pieces of chocolate containing psilocybin mushroom. They will answer questions of how they are feeling, and will be monitored for safety by two study staff members, and their vital signs will be checked every hour on the day they receive the study drug. The will be sent home with a responsible adult selected by the patient after they are felt to be safe once the effects of the drug have resolved. Participants will receive four different doses separated by about three weeks. After they complete the treatment phase, they will be contacted monthly for follow up assessment of efficacy, and safety.

03

Conditions studied

  • Obsessive-Compulsive Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 years old, and older
  • Have OCD () based on diagnostic interview using the Structured Clinical Interview for DSM-5 Research Version (SCID).
  • At least moderate severity: Yale-Brown Obsessive Compulsive Scale (YBOCS) score ≥16.
  • Failed at least one adequate trial of guideline concordant treatment.
  • Considered safe for independent living
  • Subjects must discontinue use of any of the following prescription or over the counter (OTC) products or nutritional supplements at least two weeks prior to initiating double-blind treatment:

    • Monoamine oxidase (MAOI), UGT1A10, and UGT1A9 inhibitors
    • Other active OCD treatments (cognitive behavioral therapy [CBT] or other psychotherapy; electrical or magnetic device treatments; pharmacological treatments such as antidepressant medications (e.g., SSRIs, SNRIs, MAOIs, TCAs, 5HT2 blockers, NERIs, etc.), lithium, antipsychotic drugs, 5-HT2 antagonists such as pimavanserin, and glutamatergic acting medications)

      * Note that fluoxetine must be discontinued at least 6 weeks prior to initiating double-blind treatment.

    • 5HT2 agonists (e.g., efavirenz, lorcaserin), which may alter the response to psilocybin
    • Serotonin-acting dietary supplements (e.g., 5-hydroxy-tryptophan, St. John's wort) due to potential for interaction with psilocybin and increased safety risks

Exclusion criteria

Exclusion Criteria:

  • Concurrent active substance use disorder, or a personal history of psychosis.
  • History of psychosis among first degree relatives as determined by the Family Interview for Genetic Studies (FIGS)32
  • Medical illness based on physical examination and routine blood testing that may complicate cardiovascular safety or drug metabolism or excretion. Examples include: 1) Cardiovascular conditions: lifetime history of stroke, lifetime myocardial infarction, uncontrolled hypertension (resting blood pressure >140/90 mmHg), tachycardia (resting heart rate >100 beats per minute), elongated corrected by Fridericia's formula (QTcF; interval >450 msec), participants with existing valvular heart disease, or arrhythmia (\<1 year prior to signing the ICF); 2) Metabolic conditions: subjects with diabetes should have a stable diabetes treatment regimen and no history of diabetic ketoacidosis, hyperglycemic coma, or no hypoglycemic episodes with glucose below 54 mg/dL in the 3 months prior to baseline, and fasting glucose >70 mg/dL at baseline; 3) Severe renal impairment: \<45 mL/min/1.73 m²); and Liver failure: Classes B and C.
  • Unstable (COPD) or severe sleep apnea
  • Clinically significant renal or hepatic impairment, per clinical judgment of a study physician
  • QTc ≥ 450 msec
  • Psychiatric comorbidity that may represent an acute risk to their own or other's safety, including history of bipolar disorder (I or II) in the participant or first degree relative, as well as any family history of psychosis.
  • Subjects cannot require any sedative, narcotic, or neuroleptic medications on a regular basis. Any of these medications they have taken should have been stopped long enough in the past to allow for their elimination and safe withdrawal prior to starting administration of the study drug. The specific time required will be dependent on the medication the patient was previously receiving.
  • Participants who are pregnant, breastfeeding, planning a pregnancy, or planning to donate sperm within three months post-last study drug administration.
  • Participants of or participants with partners of childbearing potential who engage in intercourse which could result in pregnancy are unwilling/unable to practice medically acceptable highly effective (double barrier, oral and injectable pharmacological contraceptives, or surgical such as vasectomy or bilateral tubal occlusion) during the study and up to three months after the last study drug administration.
  • Suicide attempt within the 12 months prior to enrollment
  • Any condition for which MRI is , at the discretion of a study investigator or the MRI technician, including: Pacemakers and defibrillators; artificial heart valves which are not MRI safe; any metal in head, spinal cord, eyes or chest; any electrical devices such as cochlear implants, nerve stimulators, deep brain stimulators, gastric pacemaker, or insulin or pain pumps; aneurysm clips; ferrous (i.e. non titanium alloy) implants in any part of the body.
  • Use within the week prior to screening of drugs of abuse as listed in the current US DOJ DEA Drugs of Abuse Resource Guide, including:

    • Cannabinoids (marijuana, synthetic cannabinoids)
    • Simulants (amphetamine, cocaine, methamphetamine, methylphenidate, modafinil)
    • Opioids (natural and synthetic),
    • Sedatives (benzodiazepines, barbiturates, GHB, zolpidem, zaleplon, zopiclone)
    • Hallucinogens (DMT, ibogaine, LSD, MDMA, psilocybin, psilocin, PSP)
  • Weight below 45kg
  • Allergy or significant intolerance to chocolate or cocoa
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Low dose 10 mg

    Whole dried psilocybin mushroom containing 10 mg of psilocybin will be mixed in a chocolate matrix and administered to the patient.

    Drug: Psilocybin 10 mg

  • Experimental
    Middle dose 20 mg

    Whole dried psilocybin mushroom containing 20 mg of psilocybin will be mixed in a chocolate matrix and administered to the patient.

    Drug: Psilocybin 20 mg

  • Experimental
    High dose 30 mg

    Whole dried psilocybin mushroom containing 30 mg of psilocybin will be mixed in a chocolate matrix and administered to the patient.

    Drug: Psilocybin 30 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Yale Brown Obsessive Compulsive Scale

    Clinician rating scale to determine severity of OCD symptoms. Scores vary from 0 to 40. Higher scores represent greater severity of OCD symptoms.

    Time frame: Baseline, Weekly for 12 weeks (Treatment phase), and Monthly for 12 month (Follow up phase).

  2. Adverse Event (AE) Tracking log

    The Adverse Event tracking log will collect information on adverse health events reported throughout the research study.

    Time frame: Weekly for 12 weeks (Treatment phase), and Monthly for 12 month (Follow up phase).

  3. Visual Analogue Scale (VAS)

    Self-reported measure of intensity or frequency of pain or other various symptoms

    Time frame: Baseline, Weekly for 12 weeks (Treatment phase), and Monthly for 12 month (Follow up phase). Scale 0 (no symptoms at all) to 100 (maximum symptom severity)

Secondary outcomes

  1. World Health Organization's quality of life assessment (WHOQOL-BREF)

    A 26-item psychometric questionnaire to measure quality of life and functional ability. Raw scores are converted to transformed scores in four health related domains. Higher scores represent higher quality of life.

    Time frame: Baseline, Weekly for 12 weeks (Treatment phase), and Monthly for 12 month (Follow up phase).

  2. Short form health survey (SF-36)

    Subject self-reporting health survey to monitor and assess functional impairment

    Time frame: Baseline, Weekly for 12 weeks (Treatment phase), and Monthly for 12 month (Follow up phase). Functionality scales are transformed to range from 0 to 100 with 0 being maximal disability and 100 being no disability.

  3. Columbia-Suicide Severity Rating Scale (C-SSRS)

    A suicide risk assessment tool for prospective monitoring of suicidal ideation and behavior.

    Time frame: Baseline, Weekly for 12 weeks (Treatment phase), and Monthly for 12 month (Follow up phase). Individuals with positive ideation or behavior scores can be categorized into low, moderate or high risk of suicide.

07

Study locations

1 of 1 sites recruiting
  • The Clinical and Translational Sciences Research Center
    Tucson, Arizona 85724, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2028, 31 months after the start.

Of 14 phase 1 interventional studies under Obsessive-Compulsive Disorder, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 57. This study's planned 31 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 22, 2025
First posted
Jan 16, 2026
StartActual
May 18, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Jan 31, 2029
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07347405
Lead sponsor
Francisco A Moreno
Collaborators
Arizona Biomedical Research Commission (ABRC)
Responsible party
Francisco A Moreno (MD, Professor of Psychiatry, University of Arizona) — Sponsor-investigator
First posted
Jan 16, 2026
Start date
May 18, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Jan 31, 2029 (estimated)
Last update
Jul 23, 2026

Study contacts

The clinical and translational research center
Contact
OCD@psychiatry.arizona.edu
(520) 626-8000
Study Coordinator
Contact
(520) 626-4804
Francisco Moreno, MD
principal investigator · University of Arizona

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Psilocybin

Start the discussion